Mobile

Randomised, double-blind, multicentric phase III trial evaluating the safety and benefit of adding everolimus to adjuvant hormone therapy in women with poor prognosis, ER+ and HER2- primary breast can...

Mise à jour : Il y a 4 ans
Référence : EUCTR2012-003187-44

Randomised, double-blind, multicentric phase III trial evaluating the safety and benefit of adding everolimus to adjuvant hormone therapy in women with poor prognosis, ER+ and HER2- primary breast cancer who remain free of disease

Femme Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The main objective of this trial is to evaluate the benefit of adding 2 years everolimus treatment to standard adjuvant endocrine treatments in patients who remain free of disease, with high risk of relapse.

Critère d'inclusion

  • Patients with high risk of relapse, ER+ and HER2- primary non-metastatic breast cancer who remain disease-free

Liens